Harvard Biosci Stock Price, News & Analysis

Harvard Bioscience (HBIO) will showcase its latest product innovations at the Society of Toxicology conference in Orlando from March 17-20, 2025. The company is presenting three major solutions:

1. The expanded SoHo™ Implantable Real-Time Telemetry Platform, which includes new biopotential monitoring devices for neurotoxicity and cardiovascular toxicology studies. The platform integrates with Ponemah data management system to automate data collection and analysis.

2. The VivaMARS™ Activity Monitoring System, a GLP-compliant platform for real-time behavioral analysis, aimed at CROs and pharmaceutical companies for neuropharmacology applications.

3. The Mesh MEA™ Organoid Platform, designed for real-time electrophysiological readings from living organoids, supporting research, safety pharmacology, and toxicology studies. The NIH has recently adopted this system for advanced neuro organoid research.

Harvard Bioscience (NASDAQ: HBIO) has announced it will release its financial results for Q4 2024 before market opening on March 12, 2025. The company will host a conference call at 8:00 AM ET on the same day to discuss the results.

Interested participants who wish to ask questions during the call must pre-register to receive dial-in numbers and a unique PIN. An audio-only webcast option will also be available through the company's investor website. The earnings release and related presentation materials will be accessible through Harvard Bioscience's Investor Relations section.

Harvard Bioscience (HBIO) has announced its participation in the upcoming Sidoti Micro Cap Virtual Conference on January 22nd, 2025. The company's Chairman and CEO Jim Green, along with CFO Jennifer Cote, will deliver a presentation at 10:00 am ET.

The presentation will be accessible through a live webcast via the investor relations section of Harvard Bioscience's website. Interested parties can view the presentation replay after its conclusion. One-on-one meetings can be arranged through the conference organizers.

Harvard Bioscience (NASDAQ: HBIO) reported Q3 2024 financial results showing revenues of $22.0 million, down from $25.4 million in Q3 2023. The company posted a net loss of $(4.8) million compared to $(1.2) million in the same period last year. Gross margin remained stable at 58.1%, while Adjusted EBITDA decreased to $1.3 million from $2.2 million.

The company completed migration to a single US enterprise resource planning system and implemented cost reduction actions expected to save $1 million quarterly starting Q4. For Q4 2024, HBIO expects revenues between $23-26 million with gross margins of 59-60% and adjusted EBITDA margin in mid-teens.

Harvard Bioscience (Nasdaq: HBIO) has scheduled its third quarter 2024 financial results announcement for November 7, 2024, before market opening. The company will host a conference call at 8:00 AM ET to discuss the results. Participants wanting to ask questions must pre-register to receive dial-in information and a PIN. An audio-only webcast option is also available through the company's investor website, where the earnings release and related presentation materials will be accessible.

Harvard Bioscience (Nasdaq: HBIO) will showcase its latest product innovations at the Society for Neuroscience (SfN) 2024 Annual Meeting in Chicago. Key highlights include:

1. Mesh MEA™ microelectrode array system: Captures electrophysiology signals from inside organoids in real-time, providing new insights into neural dynamics and brain disorders.

2. SoHo™ implantable telemetry platform: Allows data collection from multiple small animal models in a shared housing environment, integrated with the Ponemah™ data management platform.

3. VivaMARS™ activity monitoring system: Offers real-time behavioral testing for neurological research and neuropharmacology studies, reducing operating expenses and test cycle times.

The company will also display its new Heka™ patch clamp amplifiers and other products supporting in vitro and in vivo neuroscience research. Harvard Bioscience will exhibit at booth #925 at the McCormick Place Convention Center from October 6-9, 2024.

Harvard Bioscience (Nasdaq: HBIO) is showcasing its latest product innovations at the Safety Pharmacology Society Annual Meeting from September 22-25, 2024, in San Diego. The company is presenting several key solutions:

1. DSI Ponemah Data Management Platform: An integrated preclinical solution for managing and analyzing data from various studies.

2. SoHo Implantable Real-Time Telemetry: A system for small animal models, enabling longer duration studies and increased testing throughput.

3. VivaMARS Activity Monitoring System: A platform for real-time, high-throughput behavioral testing in neuropharmacology safety and toxicology studies.

4. MCS Mesh MEA Organoid Platform: Designed for organoid applications in research, safety pharmacology, and toxicology, allowing real-time electrophysiology measurements inside living organoids.

Harvard Bioscience (Nasdaq: HBIO) has announced its participation in the Sidoti Small Cap Virtual Conference on September 18th, 2024. Jim Green, Chairman and CEO, and Jennifer Cote, CFO, will represent the company with a presentation scheduled for 9:15 am ET.

The presentation will be webcast live through the investor relations section of Harvard Bioscience's website. A replay will be available shortly after the presentation concludes. Interested parties can schedule one-on-one meetings through the conference organizers.

This event provides an opportunity for investors to gain insights into Harvard Bioscience's operations and future prospects directly from its top executives.

Harvard Bioscience (NASDAQ: HBIO) reported challenging Q2 2024 financial results. Revenues decreased to $23.1 million from $28.8 million in Q2 2023. The company experienced a net loss of $2.9 million, compared to a $1.0 million loss in the same period last year. Gross margin slightly declined to 57.2% from 58.0%.

Adjusted EBITDA fell to $1.3 million from $3.9 million in Q2 2023. The company implemented cost-saving measures expected to yield $4 million in annualized savings. Due to delayed market recovery, Harvard Bioscience reduced its 2024 revenue outlook to $97-102 million, with an expected gross margin of 59-60% and adjusted EBITDA margin in high single digits.